Tetsuya Yamagata

This inventor holds 6 USPTO granted patents and 5 published patent applications. Top assignees: Modalis Therapeutics Corporation, The University of Tokyo, Astellas Pharma Gmbh. Active years: 2022-2025.

USPTO Granted Patents = 6 (Patent Applications = 5)

% Patents Active = 100.0

Average Co-Inventor Count = 4.4

ph-index = 1

Company Filing History:

6 out of 6

Modalis Therapeutics Corporation

patents

2 out of 1,352

The University of Tokyo

where one patent can have more than one assignee

Years Active: 2022-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12502418 - METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING LAMA1 GENE (2025-12-23),

2. 12152259 - Modified CAS9 protein, and use thereof (2024-11-26),

3. 11591621 - Method of treating diseases associated with elevated KRAS expression using CRISPR-GNDM system (2023-02-28),

4. 11530396 - Modified CAS9 protein, and use thereof (2022-12-20),

5. 11473071 - Method for treating muscular dystrophy by targeting utrophin gene (2022-10-18),

6. 11439692 - Method of treating diseases associated with MYD88 pathways using CRISPR-GNDM system (2022-09-13),

Title: Tetsuya Yamagata: Innovator in Gene Editing Technologies

Introduction

Tetsuya Yamagata is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of gene editing, particularly through his innovative work with CRISPR technologies. With a total of 6 patents, Yamagata's inventions are paving the way for advancements in genetic research and therapeutic applications.

Latest Patents

Yamagata's latest patents include groundbreaking inventions that enhance gene editing capabilities. One of his notable patents is for a modified CAS9 protein, which features a series of specific mutations that improve its binding ability to guide RNA while relaxing restrictions on target sequences. This innovation is particularly useful as a tool for gene editing. Another significant patent involves a method for treating diseases associated with elevated KRAS expression using a CRISPR-GNDM system. This method targets the expression regulatory region of the KRAS gene, providing a novel approach to suppressing KRAS expression in affected subjects.

Career Highlights

Throughout his career, Tetsuya Yamagata has worked with esteemed organizations such as Modalis Therapeutics Corporation and The University of Tokyo. His work in these institutions has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research in gene editing technologies.

Collaborations

Yamagata has collaborated with notable colleagues, including Yuanbo Qin and Iain Robert Thompson. These partnerships have further enriched his research and development efforts in the realm of genetic engineering.

Conclusion

Tetsuya Yamagata's innovative contributions to gene editing technologies are shaping the future of genetic research and therapeutic interventions. His work exemplifies the potential of CRISPR systems in addressing complex genetic challenges.